Happy New Year – 2016

It’s been an interesting year. When I started this site I really didn’t know what was going to happen… in most respects, it has exceeded my expectations. A Few Opening Remarks On a positive note, I genuinely felt support for the mission of trying to create a fresh dialogue around the quality and transparency of ASX-listed companies operating in this…

Congratulations Circadian

Yesterday’s announcement that Opthea (née Circadian, ASX : CIR) completely restructured its board, is good news for the company – but it is also good news for the biotech industry. Opthea’s board reshuffle, in my opinion, follows on what has been a spate of shareholder backlash to underperforming bioscience companies, and it is great to…

Optheapology

In a prior post I lightly dissed Circadian’s new name (ASX : CIR) – Opthea. In my defence, you surely knew it was coming… though I should clarify, for the avoidance of doubt, that I have always liked the name Opthea better than “sister company” Vegenics. Yuk. The word “vegenics” can only ever be credibly used in the following sentence…

Welcome, Opthea

It was with great joy and happiness today, that I read Circadian’s (ASX : CIR) AGM agenda. This is a big deal. Finally, the company has decided to change its name and re-identify itself as the inner person it always needed to be : Opthea. It’s not a perfect brand, mind-you. When I think of Opthea,…

A Cancer-Free Circadian

Today’s announcement that Circadian (ASX : CIR) has “regained” the VEGFR-3 IP from Lilly is obviously a bit of word-smithing for the reality that Lilly has elected not to proceed with the program. Ok, I will let the spin go this time, mainly because I sort of believe it’s true. Circadian’s biggest enemy is itself and its…

Compensation Matters

I have alluded to my distaste for excessive executive and board compensation several times since I started this blog. For example, my opinion is generally known that Geoff Cumming at Anteo Diagnostics (ASX : ADO) is considerably overpaid relative to the performance of his company, particularly revenue growth. Compensation  is also a multi-faceted beast and so…

Circadian : Where’s the bump?

In my prior post (last month) on Circadian Technologies (ASX : CIR), I think I gave a fairly pragmatic analysis of the company. Overall, I like the opportunity that CIR has going forward. I think there is some talent in the company and a product pipeline story (including the Lilly relationship) that could be turned into something…